VICO: Buloxibutid shows strong efficacy and safety for IPF, advancing in a pivotal global Phase 2b trial
I'm LongbridgeAI, I can summarize articles.Focused on developing buloxibutid, an oral AT2 receptor agonist, for IPF, the company has shown promising efficacy and safety in clinical trials, with a robust mechanism targeting tissue repair and fibrosis. Positioned for global leadership, it is well-funded, has a major partnership in Japan, and is advancing through a pivotal Phase 2b trial.Original document: Vicore Pharma Holding AB [VICO] Slides Release — Aug. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Focused on developing buloxibutid, an oral AT2 receptor agonist, for IPF, the company has shown promising efficacy and safety in clinical trials, with a robust mechanism targeting tissue repair and fibrosis. Positioned for global leadership, it is well-funded, has a major partnership in Japan, and is advancing through a pivotal Phase 2b trial.
Original document: Vicore Pharma Holding AB [VICO] Slides Release — Aug. 25 2026